INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.48 USD | +4.39% |
|
-.--% | -6.75% |
| Apr. 30 | Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024 | CI |
| Apr. 30 | Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29,957 | 96,872 | 57,482 | 45,398 | 63,018 | 57,440 | - | - |
| Enterprise Value (EV) 1 | 26,589 | 89,793 | 50,957 | 39,338 | 63,018 | 52,609 | 53,141 | 52,657 |
| P/E ratio | -16.3 x | -93.3 x | -18.2 x | -20.3 x | - | -68.5 x | 348 x | 40.1 x |
| Yield | - | - | - | - | - | - | 0.01% | - |
| Capitalization / Revenue | 28.6 x | 25.2 x | 13.5 x | 9.96 x | 10.2 x | 7.59 x | 5.82 x | 4.41 x |
| EV / Revenue | 25.4 x | 23.4 x | 11.9 x | 8.63 x | 10.2 x | 6.95 x | 5.39 x | 4.05 x |
| EV / EBITDA | -16.2 x | -370 x | -16.7 x | -14.3 x | -105 x | -108 x | 103 x | 27.3 x |
| EV / FCF | -13.1 x | -113 x | -16.5 x | -14 x | - | -56.5 x | -239 x | 48.1 x |
| FCF Yield | -7.64% | -0.89% | -6.06% | -7.16% | - | -1.77% | -0.42% | 2.08% |
| Price to Book | 5.87 x | 10.7 x | 5.54 x | 4.11 x | - | 4.67 x | 4.85 x | 4.31 x |
| Nbr of stocks (in thousands) | 1,262,562 | 1,402,776 | 1,462,109 | 1,534,407 | 1,621,831 | 1,622,683 | - | - |
| Reference price 2 | 23.73 | 69.06 | 39.31 | 29.59 | 38.86 | 35.40 | 35.40 | 35.40 |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,048 | 3,844 | 4,270 | 4,556 | 6,206 | 7,565 | 9,863 | 13,012 |
| EBITDA 1 | -1,638 | -242.4 | -3,045 | -2,747 | -600.1 | -485.5 | 516 | 1,931 |
| EBIT 1 | -1,676 | -310.4 | -3,113 | -3,066 | - | -898.8 | 91.53 | 1,617 |
| Operating Margin | -159.96% | -8.08% | -72.9% | -67.29% | - | -11.88% | 0.93% | 12.43% |
| Earnings before Tax (EBT) 1 | -1,720 | -858.7 | -3,051 | -2,170 | - | -797.3 | 191.4 | 1,720 |
| Net income 1 | -1,720 | -998.4 | -3,138 | -2,179 | - | -825.4 | 129 | 1,436 |
| Net margin | -164.2% | -25.97% | -73.5% | -47.83% | - | -10.91% | 1.31% | 11.04% |
| EPS 2 | -1.460 | -0.7400 | -2.160 | -1.460 | - | -0.5164 | 0.1017 | 0.8835 |
| Free Cash Flow 1 | -2,030 | -796.7 | -3,090 | -2,816 | - | -931.9 | -222.3 | 1,095 |
| FCF margin | -193.83% | -20.73% | -72.38% | -61.8% | - | -12.32% | -2.25% | 8.42% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 56.72% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 76.25% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.002500 | - |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 702 | 984.2 | 2,860 | 1,942 | 2,328 | 2,240 | 2,317 | 2,702 | 3,505 | 3,728 | 4,119 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -1,148 | -1,960 | -1,212 | -1,617 | -718.8 | - | -692.6 | -1,020 |
| Operating Margin | - | - | - | -59.12% | -84.17% | -54.11% | -69.8% | -26.61% | - | -18.58% | -24.77% |
| Earnings before Tax (EBT) | - | - | - | - | -1,876 | -998.9 | -1,172 | -256.1 | - | - | - |
| Net income | - | - | - | - | -1,963 | -950.5 | -1,229 | -139.1 | - | - | - |
| Net margin | - | - | - | - | -84.31% | -42.43% | -53.04% | -5.15% | - | - | - |
| EPS 2 | -0.8400 | -0.4600 | -0.2800 | -0.8100 | -1.350 | -0.6500 | -0.8100 | -0.0900 | - | -0.3000 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/26/20 | 3/29/21 | 8/25/21 | 3/29/22 | 8/25/22 | 3/28/23 | 8/23/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,368 | 7,079 | 6,525 | 6,059 | - | 4,831 | 4,299 | 4,783 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2,030 | -797 | -3,090 | -2,816 | - | -932 | -222 | 1,095 |
| ROE (net income / shareholders' equity) | -38.4% | -14.8% | -32.8% | -20.7% | - | -6.59% | 1% | 9.86% |
| ROA (Net income/ Total Assets) | -25.8% | -10.5% | -22.4% | -12.9% | - | -4.19% | 0.6% | 5.75% |
| Assets 1 | 6,672 | 9,533 | 14,039 | 16,916 | - | 19,687 | 21,445 | 24,968 |
| Book Value Per Share 2 | 4.040 | 6.470 | 7.100 | 7.200 | - | 7.580 | 7.300 | 8.210 |
| Cash Flow per Share 2 | -1.410 | -0.2300 | -1.390 | -1.290 | - | -0.4100 | 0.1100 | 0.9600 |
| Capex 1 | 366 | 489 | 1,066 | 897 | - | 701 | 733 | 776 |
| Capex / Sales | 34.93% | 12.72% | 24.96% | 19.68% | - | 9.27% | 7.44% | 5.97% |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
35.4
CNY
Average target price
51.17
CNY
Spread / Average Target
+44.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.80% | 86.16B | |
| +2.76% | 40.17B | |
| -16.48% | 31.47B | |
| +57.86% | 25.24B | |
| -13.58% | 15.82B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.84B | |
| +1.55% | 7.68B |
- Stock Market
- Equities
- 1801 Stock
- IVBIY Stock
- Financials Innovent Biologics, Inc.
